ArticleThe European respiratory journal2022

Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patients.

Marc Humbert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.